PE20161410A1 - Composicion farmaceutica que comprende drospirenona y kit anticonceptivo - Google Patents

Composicion farmaceutica que comprende drospirenona y kit anticonceptivo

Info

Publication number
PE20161410A1
PE20161410A1 PE2016002187A PE2016002187A PE20161410A1 PE 20161410 A1 PE20161410 A1 PE 20161410A1 PE 2016002187 A PE2016002187 A PE 2016002187A PE 2016002187 A PE2016002187 A PE 2016002187A PE 20161410 A1 PE20161410 A1 PE 20161410A1
Authority
PE
Peru
Prior art keywords
drospirenone
unit comprises
pharmaceutical composition
contraceptive kit
composition including
Prior art date
Application number
PE2016002187A
Other languages
English (en)
Inventor
Jose Velada
Dominique Drouin
Original Assignee
Perrin Philippe
Laboratorios Leon Farma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42671710&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20161410(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Perrin Philippe, Laboratorios Leon Farma Sa filed Critical Perrin Philippe
Publication of PE20161410A1 publication Critical patent/PE20161410A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se refiere a un kit anticonceptivo que comprende una o mas unidades de envasado, en el que cada unidad de envasado comprende 21 a 28 unidades de dosificacion activas diarias, y en el que cada unidad de dosificacion activa diaria comprende por lo menos 2 mg de drospirenona y esta libre de estrogenos. Cada unidad de dosificacion activa diaria comprende drospirenona en forma de particulas no micronizadas, con una superficie especifica de 2000 cm2/g hasta 8500 cm2/g, y con una distribucion del tamano de particulas que, en su ambito mas amplio, se caracteriza por: (i) d90 inferior a 100 um; (ii) d50 desde 10 um hasta 60 um; y (iii) d10 de mas de 3 um. Tambien se refiere a composiciones farmaceuticas que comprenden por lo menos 2 mg de particulas no micronizadas de drospirenona con las caracteristicas de superficie especifica y distribucion del tamano de particulas anteriormente senaladas, libres de estrogenos.
PE2016002187A 2010-06-29 2011-06-28 Composicion farmaceutica que comprende drospirenona y kit anticonceptivo PE20161410A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10305708 2010-06-29
US36839610P 2010-07-28 2010-07-28

Publications (1)

Publication Number Publication Date
PE20161410A1 true PE20161410A1 (es) 2017-01-10

Family

ID=42671710

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2016002187A PE20161410A1 (es) 2010-06-29 2011-06-28 Composicion farmaceutica que comprende drospirenona y kit anticonceptivo
PE2012002518A PE20130780A1 (es) 2010-06-29 2011-06-28 Composion farmaceutica que comprende drospirenona y kit anticonceptivo

Family Applications After (1)

Application Number Title Priority Date Filing Date
PE2012002518A PE20130780A1 (es) 2010-06-29 2011-06-28 Composion farmaceutica que comprende drospirenona y kit anticonceptivo

Country Status (23)

Country Link
US (6) US11452695B2 (es)
EP (3) EP4056186A1 (es)
JP (1) JP5810159B2 (es)
KR (3) KR20130048227A (es)
AR (1) AR081670A1 (es)
BR (1) BR112012033391B1 (es)
CA (3) CA3003062C (es)
CY (2) CY1122544T1 (es)
DK (1) DK3632448T3 (es)
EA (1) EA028680B1 (es)
ES (1) ES2908657T3 (es)
FR (2) FR20C1020I1 (es)
HR (1) HRP20220332T1 (es)
HU (3) HUE058176T2 (es)
LT (2) LT3632448T (es)
NO (1) NO2020015I1 (es)
NZ (1) NZ605176A (es)
PE (2) PE20161410A1 (es)
PL (2) PL3632448T3 (es)
PT (1) PT3632448T (es)
RS (2) RS59826B1 (es)
SI (2) SI2588114T1 (es)
WO (1) WO2012000981A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10849857B2 (en) 2010-07-28 2020-12-01 Laboratorios Leon Farma Sa Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
US11351122B1 (en) 2010-07-28 2022-06-07 Laboratorios Leon Farma Sa Synthetic progestogens and pharmaceutical compositions comprising the same
AR081670A1 (es) * 2010-06-29 2012-10-10 Leon Farma Sa Lab Composicion farmaceutica que comprende drospirenona y kit anticonceptivo
US9603860B2 (en) 2010-07-28 2017-03-28 Laboratorios Leon Farma Sa Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
EP2383279A1 (en) 2011-07-19 2011-11-02 Pantarhei Bioscience B.V. Process for the preparation of estetrol
NO3106148T3 (es) 2015-06-18 2018-08-11
WO2016203009A1 (en) 2015-06-18 2016-12-22 Mithra Pharmaceuticals S.A. Orodispersible tablet containing estetrol
GEP20217243B (en) 2015-06-18 2021-04-26 Sprl Estetra Orodispersible dosage unit containing an estetrol component
HUE054551T2 (hu) 2015-06-18 2021-09-28 Estetra Sprl Ösztetrolt tartalmazó, szájban diszpergálódó tabletta
ES2970532T3 (es) * 2015-06-23 2024-05-29 Laboratorios Leon Farma Sa Anticonceptivo basado en drospirenona para una paciente que presenta exceso de peso
EP3108889A1 (en) 2015-06-23 2016-12-28 Philippe Perrin Drospirenone-based contraceptive for a female patient affected with excess weight
KR20220144885A (ko) 2016-08-05 2022-10-27 에스테트라, 소시에떼 아 레스폰서빌리떼 리미떼 월경통 및 생리통의 관리방법
JOP20200260A1 (ar) 2018-04-19 2019-10-19 Estetra Sprl مركبات واستخداماتها للتخفيف من الأعراض المصاحبة لانقطاع الطمث
TWI801561B (zh) 2018-04-19 2023-05-11 比利時商依思特拉私人有限責任公司 化合物及其用於緩解絕經相關症狀的用途
EP4134082A1 (en) 2021-08-12 2023-02-15 Chemo Research, S.L. Method for treating endometriosis and providing effective contraception
WO2023152658A1 (en) 2022-02-10 2023-08-17 Lupin Limited Slow release drospirenone tablet composition
WO2023165988A1 (en) 2022-03-01 2023-09-07 Chemo Research, S.L. Chewable oral contraceptive

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2652761C2 (de) 1976-11-16 1985-11-21 Schering AG, 1000 Berlin und 4709 Bergkamen 15,16-Methylen-Spirolactone, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel
DE3022337A1 (de) 1980-06-11 1982-01-07 Schering Ag Berlin Und Bergkamen, 1000 Berlin Praeparate zur kontrazeption und zur behandlung gynaekologischer stoerungen
IE67187B1 (en) 1990-06-15 1996-03-06 Merck & Co Inc A crystallization method to improve crystal structure and size
GB2256648B (en) 1991-05-29 1995-08-30 Colorcon Ltd Wax polish composition
DE19633685C1 (de) 1996-08-12 1997-10-09 Schering Ag Verfahren zur Herstellung von Drospirenon (6beta,7beta;15 beta,16beta-Dimethyl-en-3-oxo-17alpha-pregn-4-en-21,17-carbolacton, DRSP) sowie 7alpha-(3-Hydroxy-1-propyl)-6beta,7beta;15beta, 16beta-dimethylen-5beta-androstan-3beta,5,17beta-triol (ZK 92836) und 6beta,7beta;15beta,16beta-dimethylen-5beta-hydroxy-3-oxo-17alpha-androstan-21,17-carbolacton (90965) als Zwischenprodukte des Verfahrens
NZ517845A (en) 1999-08-31 2004-12-24 Schering Ag Pharmaceutical combination of ethinylestradiol and drospirenone for use as a contraceptive
US6787531B1 (en) 1999-08-31 2004-09-07 Schering Ag Pharmaceutical composition for use as a contraceptive
US20020132801A1 (en) 2001-01-11 2002-09-19 Schering Aktiengesellschaft Drospirenone for hormone replacement therapy
CN101934078A (zh) 2000-01-18 2011-01-05 拜耳先灵医药股份有限公司 包含屈螺酮和雌激素的药物组合物及其应用
US20040087563A1 (en) 2002-11-05 2004-05-06 Siegfried Mayerhofer Hormone replacement therapy with cardiovascular protection using antialdosteronic progestins
US7786101B2 (en) 2002-11-05 2010-08-31 Bayer Schering Pharma Ag Cardiovascular protection using anti-aldosteronic progestins
US20050220825A1 (en) 2004-03-10 2005-10-06 Adrian Funke Molecular dispersions of drospirenone
DE602005014227D1 (de) 2004-03-10 2009-06-10 Bayer Schering Pharma Ag Zusammensetzungen aus drospirenon in molekularer dispersion
MY142989A (en) 2004-03-10 2011-02-14 Bayer Schering Pharma Ag Stabilised supersaturated solids of lipophilic drugs
MY151322A (en) 2004-04-30 2014-05-15 Bayer Ip Gmbh Management of breakthrough bleeding in extended hormonal contraceptive regimens
PE20060378A1 (es) 2004-07-07 2006-06-02 Wyeth Corp Regimenes y kits de progestina ciclica
EP1625849A1 (en) 2004-08-09 2006-02-15 Liconsa, Liberacion Controlada de Sustancias Activas, S.A. Pharmaceutical composition comprising drospirenone and ethynylestradiol
ITMI20042338A1 (it) 2004-12-06 2005-03-06 Ind Chimica Srl Processo per la preparazione di drospirenone
US20060293295A1 (en) 2005-05-13 2006-12-28 Kai Strothmann Pharmaceutical composition comprising progestogens and/or estrogens and 5-methyl- (6S)-tetrahydrofolate
US8475838B2 (en) 2005-06-03 2013-07-02 Sandoz Ag Rapidly-dissolving pharmaceutical composition for inhibiting ovulation
TW200727920A (en) 2005-06-21 2007-08-01 Organon Nv New regimens for oral monophasic contraceptives
ATE403668T1 (de) 2005-07-21 2008-08-15 Bayer Schering Pharma Ag Verfahren zur herstellung von 3-oxo-pregn-4-en-21,17-carbolactonen durch die metallfreie oxidation von 17-(3-hydroxypropyl)-3,17- dihydroxyandrostanen
CN101489563A (zh) 2006-07-06 2009-07-22 拜耳先灵医药股份有限公司 用于避孕和预防先天性畸形风险的药物制剂
EP2063870A2 (en) * 2006-09-16 2009-06-03 Bayer Schering Pharma Aktiengesellschaft Oral modified release formulations
TW200930343A (en) 2007-09-21 2009-07-16 Organon Nv Drug delivery system
KR20100117603A (ko) 2008-02-13 2010-11-03 바이엘 쉐링 파마 악티엔게젤샤프트 안정화 효과를 갖는 약물 전달 시스템
WO2009138224A1 (en) 2008-05-14 2009-11-19 Helm Ag Pharmaceutical composition comprising drospirenone
DE102008037025C5 (de) 2008-08-08 2016-07-07 Jesalis Pharma Gmbh Verfahren zur Herstellung kristalliner Wirkstoff-Mikropartikel bzw. einer Wirkstoffpartikel-Festkörperform
TW201008569A (en) * 2008-08-08 2010-03-01 Bayer Schering Pharma Ag Progestin-containing drug delivery system
US11351122B1 (en) 2010-07-28 2022-06-07 Laboratorios Leon Farma Sa Synthetic progestogens and pharmaceutical compositions comprising the same
AR081670A1 (es) * 2010-06-29 2012-10-10 Leon Farma Sa Lab Composicion farmaceutica que comprende drospirenona y kit anticonceptivo
US10849857B2 (en) 2010-07-28 2020-12-01 Laboratorios Leon Farma Sa Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
US9603860B2 (en) 2010-07-28 2017-03-28 Laboratorios Leon Farma Sa Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same

Also Published As

Publication number Publication date
HRP20220332T1 (hr) 2022-05-13
SI2588114T1 (sl) 2020-07-31
KR20210013663A (ko) 2021-02-04
US20230046871A1 (en) 2023-02-16
EA201291372A1 (ru) 2013-06-28
AU2011273605B2 (en) 2016-05-26
CY1122544T1 (el) 2021-01-27
US20220339107A1 (en) 2022-10-27
BR112012033391A8 (pt) 2018-04-17
CA2803721C (en) 2018-06-12
RS59826B1 (sr) 2020-02-28
US20220339106A1 (en) 2022-10-27
US11491113B1 (en) 2022-11-08
SI3632448T1 (sl) 2022-04-29
FR20C1020I1 (fr) 2020-08-07
FR22C1031I1 (fr) 2022-09-09
KR102539030B1 (ko) 2023-05-31
PT3632448T (pt) 2022-03-07
NO2020015I1 (no) 2020-06-11
LTPA2022513I1 (es) 2022-07-11
EP4056186A1 (en) 2022-09-14
US11951213B2 (en) 2024-04-09
HUS2200018I1 (hu) 2022-06-28
US20220241209A1 (en) 2022-08-04
PL3632448T3 (pl) 2022-05-02
CA3061421C (en) 2021-06-01
PL2588114T3 (pl) 2020-05-18
NZ605176A (en) 2015-02-27
EP3632448B1 (en) 2022-01-12
US11452695B2 (en) 2022-09-27
CA3003062C (en) 2019-12-31
BR112012033391A2 (pt) 2016-11-22
JP5810159B2 (ja) 2015-11-11
AU2011273605A8 (en) 2016-07-28
FR22C1031I2 (fr) 2023-12-22
WO2012000981A1 (en) 2012-01-05
CA2803721A1 (en) 2012-01-05
PE20130780A1 (es) 2013-07-06
CA3061421A1 (en) 2012-01-05
LT3632448T (lt) 2022-03-25
HUE058176T2 (hu) 2022-07-28
CA3003062A1 (en) 2012-01-05
ES2908657T3 (es) 2022-05-03
KR20170085604A (ko) 2017-07-24
US20230372248A1 (en) 2023-11-23
BR112012033391B1 (pt) 2020-02-27
CY1125061T1 (el) 2023-06-09
EP2588114A1 (en) 2013-05-08
DK3632448T3 (da) 2022-02-07
US11504334B2 (en) 2022-11-22
JP2013529665A (ja) 2013-07-22
KR102164693B1 (ko) 2020-10-13
RS63027B1 (sr) 2022-04-29
US20220339165A1 (en) 2022-10-27
EA028680B1 (ru) 2017-12-29
KR20130048227A (ko) 2013-05-09
HUS2000016I1 (hu) 2020-07-28
EP3632448A1 (en) 2020-04-08
AR081670A1 (es) 2012-10-10
AU2011273605A1 (en) 2013-01-17
US11478487B1 (en) 2022-10-25
EP2588114B1 (en) 2019-12-25

Similar Documents

Publication Publication Date Title
PE20161410A1 (es) Composicion farmaceutica que comprende drospirenona y kit anticonceptivo
AR115939A2 (es) Composición que contiene palmitoil-etanolamida ultra-micronizada
RS52421B (en) RAZAGILIN FORMULATION WITH DELAYED RELEASE
MD3310346T2 (ro) Comprimată orodispersabilă ce conține estetrol
NZ611467A (en) Rapidly dispersing granules, orally disintegrating tablets and methods
MX2015016112A (es) Forma de dosificacion resistente al uso indebido que contiene una o mas particulas.
MX352434B (es) Formulaciones topicas que tienen biodisponibilidad aumentada.
MY173715A (en) Delayed release, oral dosage compositions that contain amorphous cddo-me
NZ594022A (en) Pharmaceutical composition comprising linagliptin and optionally a sglt2 inhibitor, and uses thereof
WO2011076749A3 (en) Solid pharmaceutical dosage form of ticagrelor
EP2571486A4 (en) DRY POWDER INHALATION COMPOSITION
MX356702B (es) Formas de dosificación sólidas orales con dosis muy bajas para la hrt.
MX2017016274A (es) Unidad de dosificacion orodispersable que contiene un componente estetrol.
AU2011336397A8 (en) Chemokine CXCR4 receptor modulators and uses related thereto
AR084932A1 (es) Composicion oftalmica que comprende un androgeno y su uso para la fabricacion de un medicamento util para el tratamiento de una enfermedad ocular resultante de una deficiencia androgenica
MX2012012837A (es) Composiciones farmaceuticas y metodos para su elaboracion.
NZ598427A (en) Stabilized amorphous forms of imatinib mesylate with cyclodextrin complex
HK1168016A1 (en) Oral dosage form, comprising at least one biologically active agent, formulation auxiliary substances and magnetizable particles
AR095691A1 (es) FORMULACIÓN DE L-5-METILTETRAHIDROFOLATO DE CALCIO AMORFO (L-5-MTHF-Ca), PROCEDIMIENTO, USO
BR112014030700A2 (pt) formulações em spray com características reduzidas de obstrução/sedimentação
TW201129386A (en) Microcrystalline cellulose and calcium phosphate compositions useful as pharmaceutical excipients
WO2013057741A3 (en) Pharmaceutical compositions of ursodeoxycholic acid
MX2021005119A (es) Formulacion aerosolizada.
TW200612962A (en) Estriol and estetrol prodrugs
MX2013008120A (es) Composicion cosmetica fotoprotectora de rayos ultravioleta.